



Canadian
Cancer Clinical
Trials Network

Canadian Cancer Clinical Trials Network

Quarterly Performance Report

Quarter 2, FY 2019/20 (Year 6): July 1- September 30, 2019


Table of Contents

| | |
|---|----|
| Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials | 2 |
| Patient Recruitment at All Network Sites | 2 |
| Number of patients recruited and number of Portfolio trials per Network site (by fiscal year) | 3 |
| Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – BC, Alberta and Manitoba..... | 3 |
| Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba..... | 4 |
| Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Ontario | 5 |
| Number of active recruiting 3CTN Portfolio trials – Ontario | 6 |
| Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Atlantic Region and Quebec | 7 |
| Number of Active Recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec..... | 8 |
| Section B: 3CTN Portfolio Metrics..... | 9 |
| Active Recruiting Portfolio Trials by Disease Site and Phase | 9 |
| Portfolio Impact Assessment | 10 |
| Overview of Portfolio Applications – Process Efficiency..... | 11 |

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

Patient Recruitment at All Network Sites

Objective: To improve patient access to academic clinical trials and improve patient recruitment by greater than 75% within four years.



Notes:

- 936 patients were recruited to Portfolio trials in Quarter 2. Y6 target is to achieve 60% above pre-3CTN baseline.
- YTD accrual of 1922 patients fell short of the target of 1983 patients for the Network overall.
- The TMIST trial being conducted by 2 Ontario cancer centres and 2 Quebec cancer centres contributed 553 (29%) patients to the Network total recruitment during this period.
- Overall, 33% of Adult Sites (14 out of 42) are on track for meeting the annual target and 16% (7 out of 42) have achieved their Y6 target at this time.
- Pediatric centres don't have a recruitment target, therefore the graph shows Pediatric progress to Pre-3CTN baseline recruitment.

Number of patients recruited and number of Portfolio trials per Network site (by fiscal year)

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – BC, Alberta and Manitoba

| Network Site | Pre-3CTN Baseline | Y2 Total | Y3 Total | Y4 Total | Y5 Total | Y6Q1 2019-20 | Y6Q2 2019-20 | Y6 Total | % of Y6 Baseline | % to Y6 Target* |
|--|-------------------|------------|------------|------------|------------|--------------|--------------|------------|------------------|-----------------|
| CancerCare Manitoba | 99 | 72 | 102 | 90 | 98 | 16 | 17 | 33 | 33% | 21% |
| Prairie Mountain Health | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0% | 0% |
| CancerCare Manitoba - Pediatrics | 18 | 20 | 14 | 17 | 4 | 0 | 1 | 1 | 6% | - |
| Manitoba | 118 | 92 | 116 | 107 | 103 | 16 | 18 | 34 | 29% | 18% |
| BC Cancer Agency - Vancouver Centre | 106 | 117 | 152 | 127 | 107 | 29 | 22 | 51 | 48% | 30% |
| Abbotsford Centre | 16 | 28 | 14 | 22 | 22 | 0 | 1 | 1 | 6% | 4% |
| Centre for the North, Prince George | 1 | 6 | 4 | 8 | 9 | 5 | 4 | 9 | 900% | 563% |
| Sindi Ahluwalia Hawkins Centre for the Southern Interior | 38 | 40 | 30 | 28 | 38 | 10 | 6 | 16 | 42% | 26% |
| Vancouver Island Centre | 26 | 44 | 69 | 64 | 69 | 18 | 12 | 30 | 115% | 72% |
| British Columbia Cancer Agency | 187 | 235 | 269 | 249 | 245 | 62 | 45 | 107 | 57% | 36% |
| Alberta Health Services, Cross Cancer Institute | 102 | 112 | 137 | 99 | 103 | 20 | 16 | 36 | 35% | 22% |
| Alberta Health Services, Tom Baker Cancer Centre | 76 | 140 | 125 | 154 | 139 | 31 | 14 | 45 | 59% | 37% |
| Alberta Health Services | 178 | 252 | 262 | 253 | 242 | 51 | 30 | 81 | 46% | 28% |
| Western Region Total | 483 | 579 | 647 | 609 | 590 | 129 | 93 | 222 | 46% | 30% |

* Pediatric sites don't have recruitment targets and are excluded in province and regional "% to Y6 Target" calculations

Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba

| Network Site | Pre-3CTN Baseline | Y5Q1 2018-19 | Y5Q2 2018-19 | Y5Q3 2018-19 | Y5Q4 2018-19 | Y6Q1 2019-20 | Y6Q2 2019-20 |
|--|----------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| CancerCare Manitoba | 37 | 28 | 27 | 29 | 23 | 22 | 19 |
| Prairie Mountain Health | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| CancerCare Manitoba - Pediatrics | 19 | 17 | 17 | 15 | 13 | 10 | 9 |
| BC Cancer Agency - Vancouver Centre | 50 | 25 | 25 | 27 | 27 | 26 | 25 |
| Abbotsford Centre | 6 | 4 | 4 | 4 | 4 | 5 | 5 |
| Centre for the North, Prince George | 2 | 3 | 3 | 3 | 3 | 2 | 2 |
| Sindi Ahluwalia Hawkins Centre for the Southern Interior | 23 | 9 | 10 | 6 | 6 | 5 | 5 |
| Vancouver Island Centre | 12 | 5 | 6 | 5 | 5 | 8 | 7 |
| Alberta Health Services, Cross Cancer Institute | 29 | 29 | 28 | 30 | 29 | 27 | 26 |
| Alberta Health Services, Tom Baker Cancer Centre | 20 | 29 | 32 | 32 | 30 | 30 | 34 |

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Ontario

| Network Site | Pre-3CTN Baseline | Y2 Total | Y3 Total | Y4 Total | Y5 Total | Y6Q1 2019-20 | Y6Q2 2019-20 | Y6 Total | % of Y6 Baseline | % to Y6 Target* |
|--|-------------------|-------------|-------------|-------------|-------------|--------------|--------------|-------------|------------------|-----------------|
| London Health Sciences Centre | 186 | 172 | 187 | 169 | 248 | 67 | 55 | 122 | 66% | 41% |
| Grand River Regional Cancer Centre | 20 | 13 | 43 | 32 | 34 | 2 | 5 | 7 | 35% | 22% |
| Windsor Regional Cancer Centre | 14 | 17 | 63 | 32 | 16 | 0 | 3 | 3 | 21% | 13% |
| Hamilton Health Sciences, Juravinski Cancer Centre | 181 | 231 | 247 | 454 | 345 | 65 | 40 | 105 | 58% | 36% |
| Cambridge Memorial Hospital | 11 | 2 | 5 | 4 | 5 | 1 | 3 | 4 | 36% | 23% |
| St. Joseph's Healthcare Hamilton | 21 | 30 | 54 | 74 | 40 | 9 | 3 | 12 | 57% | 36% |
| Walker Family Cancer Centre, Niagara Health System | 17 | 22 | 13 | 23 | 37 | 17 | 5 | 22 | 129% | 81% |
| Sunnybrook Health Sciences Centre, Sunnybrook Research Institute | 141 | 229 | 398 | 363 | 651 | 155 | 163 | 318 | 226% | 141% |
| Humber River Hospital | 1 | 2 | 1 | 9 | 7 | 0 | 0 | 0 | 0% | 0% |
| Michael Garron Hospital (Toronto East General Hospital) | 2 | 2 | 1 | 7 | 2 | 0 | 0 | 0 | 0% | 0% |
| Princess Margaret Cancer Centre | 396 | 384 | 533 | 473 | 720 | 121 | 128 | 249 | 63% | 39% |
| Markham Stouffville Hospital | 1 | 0 | 28 | 9 | 2 | 2 | 0 | 2 | 200% | 125% |
| Mount Sinai Hospital | 21 | 12 | 40 | 7 | 12 | 2 | 0 | 2 | 10% | 6% |
| Northeast Cancer Centre - Health Sciences North | 24 | 17 | 12 | 9 | 18 | 3 | 2 | 5 | 21% | 13% |
| North York General Hospital | 1 | 4 | 8 | 11 | 9 | 0 | 1 | 1 | 100% | 63% |
| Royal Victoria Regional Health Centre | 8 | 18 | 58 | 23 | 9 | 1 | 4 | 5 | 63% | 39% |
| Southlake Regional Health Centre | 10 | 15 | 75 | 26 | 68 | 8 | 10 | 18 | 180% | 113% |
| St. Michael's Hospital | 19 | 0 | 27 | 2 | 1 | 0 | 0 | 0 | 0% | 0% |
| Thunder Bay Regional Health Sciences Centre | 26 | 3 | 46 | 16 | 25 | 2 | 0 | 2 | 8% | 5% |
| Trillium Health Partners | 27 | 5 | 51 | 10 | 12 | 2 | 3 | 5 | 19% | 12% |
| William Osler Health System | 1 | 0 | 29 | 13 | 0 | 1 | 5 | 6 | 600% | 375% |
| The Ottawa Hospital Cancer Centre | 132 | 238 | 396 | 500 | 850 | 216 | 172 | 388 | 294% | 184% |
| Cancer Centre of Southeastern Ontario at Kingston General Hospital | 41 | 58 | 122 | 84 | 72 | 22 | 16 | 38 | 93% | 58% |
| Lakeridge Health, RSM Durham Regional Cancer Centre | 22 | 26 | 70 | 18 | 15 | 8 | 7 | 15 | 68% | 43% |
| NRCC Ontario Subtotal | 1323 | 1500 | 2507 | 2368 | 3198 | 704 | 625 | 1329 | 100% | 63% |

Number of active recruiting 3CTN Portfolio trials – Ontario

| Network Site | Pre-3CTN Baseline | Y5Q1 2018-19 | Y5Q2 2018-19 | Y5Q3 2018-19 | Y5Q4 2018-19 | Y6Q1 2019-20 | Y6Q2 2019-20 |
|--|----------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| London Health Sciences Centre | 79 | 45 | 46 | 46 | 40 | 47 | 52 |
| Grand River Regional Cancer Centre | 11 | 8 | 8 | 8 | 8 | 6 | 7 |
| Windsor Regional Cancer Centre | 4 | 4 | 4 | 5 | 5 | 4 | 4 |
| Hamilton Health Sciences, Juravinski Cancer Centre | 51 | 29 | 27 | 30 | 32 | 22 | 26 |
| Cambridge Memorial Hospital | 5 | 2 | 2 | 3 | 2 | 2 | 2 |
| St. Joseph's Healthcare Hamilton | 2 | 3 | 2 | 2 | 3 | 1 | 1 |
| Walker Family Cancer Centre, Niagara Health System | 10 | 8 | 7 | 8 | 7 | 6 | 6 |
| Sunnybrook Health Sciences Centre, Sunnybrook Research Institute | 10 | 32 | 34 | 34 | 35 | 34 | 36 |
| Humber River Hospital | 0 | 3 | 3 | 2 | 2 | 2 | 2 |
| Michael Garron Hospital (Toronto East General Hospital) | 3 | 2 | 2 | 2 | 2 | 1 | 1 |
| Princess Margaret Cancer Centre | 91 | 71 | 74 | 81 | 86 | 78 | 88 |
| Markham Stouffville Hospital | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Mount Sinai Hospital | 6 | 4 | 4 | 4 | 4 | 4 | 5 |
| Northeast Cancer Centre - Health Sciences North | 10 | 6 | 7 | 7 | 8 | 7 | 7 |
| North York General Hospital | 0 | 3 | 4 | 3 | 3 | 3 | 5 |
| Royal Victoria Regional Health Centre | 5 | 8 | 6 | 6 | 6 | 6 | 6 |
| Southlake Regional Health Centre | 3 | 9 | 10 | 10 | 10 | 9 | 8 |
| St. Michael's Hospital | 4 | 1 | 1 | 1 | 2 | 2 | 2 |
| Thunder Bay Regional Health Sciences Centre | 8 | 5 | 5 | 5 | 5 | 5 | 5 |
| Trillium Health Partners | 9 | 3 | 3 | 3 | 4 | 4 | 4 |
| William Osler Health System | 0 | 1 | 1 | 2 | 2 | 1 | 2 |
| The Ottawa Hospital Cancer Centre | 56 | 38 | 37 | 41 | 51 | 41 | 36 |
| Cancer Centre of Southeastern Ontario at Kingston General Hospital | 18 | 26 | 25 | 25 | 26 | 21 | 33 |
| Lakeridge Health, RSM Durham Regional Cancer Centre | 13 | 3 | 4 | 3 | 3 | 3 | 3 |

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Atlantic Region and Quebec

| Network Site | Pre-3CTN Baseline | Y2 Total | Y3 Total | Y4 Total | Y5 Total | Y6Q1 2019-20 | Y6Q2 2019-20 | Y6 Total | % of Y6 Baseline | % to Y6 Target* |
|--|----------------------|-------------|-------------|-------------|-------------|-----------------|-----------------|-------------|---------------------|--------------------|
| Nova Scotia Health Authority | 39 | 40 | 52 | 45 | 42 | 7 | 4 | 11 | 28% | 18% |
| Eastern Regional Health Authority | 15 | 4 | 12 | 8 | 15 | 3 | 7 | 10 | 67% | 42% |
| Janeway Child Health Centre | 4 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0% | - |
| Atlantic Total | 58 | 47 | 68 | 57 | 57 | 10 | 11 | 21 | 36% | 24% |
| CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM) | 87 | 76 | 161 | 149 | 66 | 40 | 34 | 74 | 85% | 53% |
| CISSS de l'Outaouais | 3 | 0 | 4 | 32 | 1 | 0 | 4 | 4 | 133% | 83% |
| CHU de Québec – Université Laval, adults | 180 | 25 | 144 | 236 | 99 | 43 | 105 | 148 | 82% | 51% |
| CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS) | 46 | 16 | 70 | 55 | 18 | 18 | 13 | 31 | 67% | 42% |
| Centre Hospitalier de l'Université de Montréal (CHUM) | 153 | 59 | 123 | 149 | 112 | 20 | 11 | 31 | 20% | 13% |
| CIUSSS du Nord-de-l'Île-de-Montréal(CIUSSS NDIM) | 3 | 0 | 4 | 16 | 8 | 2 | 14 | 16 | 533% | 333% |
| CIUSSS de l'Est-de-l'Île-de-Montréal(CIUSSS-EDIM) | 60 | 12 | 51 | 49 | 23 | 7 | 4 | 11 | 18% | 11% |
| CHU de Quebec - Pediatrics | 17 | 14 | 7 | 17 | 22 | 5 | 5 | 10 | 59% | - |
| Centre hospitalier universitaire de Sainte-Justine | 42 | 26 | 44 | 40 | 38 | 12 | 5 | 17 | 40% | - |
| Montreal Children's Hospital | 24 | 23 | 14 | 20 | 8 | 1 | 3 | 4 | 17% | - |
| Quebec Total | 615 | 251 | 622 | 763 | 395 | 148 | 198 | 346 | 56% | 37% |
| Eastern Region Total | 673 | 298 | 690 | 820 | 452 | 158 | 209 | 367 | 55% | 36% |

* Pediatric sites don't have recruitment targets and are excluded in province and regional “% to Y6 Target” calculations.


Number of Active Recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec

| Network Site | Pre-3CTN Baseline | Y5Q1 2018-19 | Y5Q2 2018-19 | Y5Q3 2018-19 | Y5Q4 2018-19 | Y6Q1 2019-20 | Y6Q2 2019-20 |
|--|----------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Nova Scotia Health Authority | 14 | 12 | 16 | 17 | 17 | 19 | 14 |
| Eastern Regional Health Authority | 6 | 4 | 6 | 5 | 6 | 8 | 9 |
| Janeway Child Health Centre | 5 | 11 | 9 | 9 | 9 | 5 | 9 |
| CISSS de l'Outaouais | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM) | 27 | - | - | - | - | 18 | 15 |
| CHU de Québec – Université Laval, adults | 39 | 19 | 20 | 26 | 26 | 26 | 26 |
| CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS) | 10 | 13 | 11 | 13 | 16 | 16 | 16 |
| Centre Hospitalier de l'Université de Montréal (CHUM) | 28 | 32 | 34 | 37 | 37 | 33 | 30 |
| CIUSSS du Nord-de-l'Île-de-Montréal(CIUSSS NDIM) | 4 | 2 | 2 | 2 | 2 | 2 | 3 |
| CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS-EDIM) | 6 | 12 | 13 | 11 | 10 | 10 | 8 |
| CHU de Quebec - Pediatrics | 11 | 13 | 16 | 17 | 15 | 17 | 15 |
| Centre hospitalier universitaire de Sainte-Justine | 9 | 30 | 22 | 22 | 24 | 17 | 18 |
| Montreal Children's Hospital | 5 | 25 | 25 | 20 | 21 | 12 | 16 |

Section B: 3CTN Portfolio Metrics

Active Recruiting Portfolio Trials by Disease Site and Phase

Objective: To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



Portfolio Impact Assessment

Objective: To provide a more specific and translatable impact description of 3CTN Portfolio trials for existing and future stakeholders.

| Trial Categories of Interest | Breakthrough | Enhancement/derivative | Platform | Sustaining | Cross cancer | N/A | Total # of Trials per Study Criteria |
|---|--------------|------------------------|------------|------------|--------------|----------|--------------------------------------|
| Novel therapy | 8 | 5 | 14 | - | 1 | - | 27 |
| Patient management | - | 5 | 50 | 23 | 5 | 2 | 80 |
| Precision medicine | 6 | 16 | 41 | 4 | 4 | 2 | 69 |
| Rare cancer setting | 3 | 9 | 29 | 8 | 1 | 1 | 50 |
| Vulnerable populations | - | 5 | 18 | 8 | 1 | - | 31 |
| Lifestyle interventions | - | - | 7 | 1 | - | - | 8 |
| N/A | - | - | 8 | - | - | - | 8 |
| Total # of Trials per Study Criteria | 8 | 18 | 114 | 30 | 9 | 2 | |

Note: A trial may fit into more than one categories; N=172 unique count of reviewed trials.

To see the Impact Analysis of the Portfolio click [here](#).

Overview of Portfolio Applications – Process Efficiency

Objective: To improve Portfolio application processing time.

Portfolio Approval Process Timeline¹

| Calendar Year | # Applications Completed | Average Application Processing Time (days) | Median Application Processing Time (days) |
|---------------|--------------------------|--|---|
| 2015 | 89 | 24 | 8 |
| 2016 | 70 | 24 | 6 |
| 2017 | 45 | 19 | 6 |
| 2018 | 46 | 21 | 6 |
| 2019 | 39 | 35 | 1 |

Facilitated Peer Review (FPR) Process²

| Calendar Year | # Applications Completed | Average FPR Time (days) | Median FPR Time (days) |
|---------------|--------------------------|-------------------------|------------------------|
| 2015 | 6 | 47 | 39 |
| 2016 | 10 | 98 | 79 |
| 2017 | 4 | 79 | 74 |
| 2018 | 10 | 84 | 78 |
| 2019 | 12 | 99 | 83 |

1. From application received to approve/decline the application for period, Jan 13, 2015 to December 9, 2019.
2. From start of peer review to date (i.e. site agreed to pursue peer review) to last reviewer submitted completed peer review package to 3CTN (approved trials only).

Additional links to Portfolio Application Interactive reports:

[Portfolio Application Overview](#)

[Portfolio Application Efficiency Metrics](#)

3CTN Performance Report

Recruitment database lock & Portfolio snapshot date: December 9, 2019